RxDoctor Payments Data

Ihsan Safi, MD

Internal Medicine · Bluefield, VANPI 1538128863

Payments from drug & device makers

$4,684in general payments, 2019–2025

Across 350 payments — averaging $13.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$584
  • AbbVie$521
  • Amarin Pharma, Inc.$225
  • Bayer$218
  • Kowa Pharmaceuticals America, Inc.$203
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,64299%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,684 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$110,962
Medicare patients
311
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide319$450,809
JardianceEmpagliflozin233$305,555
FarxigaDapagliflozin Propanediol184$194,307
MounjaroTirzepatide146$183,800
TrulicityDulaglutide107$168,660
Tresiba Flextouch U-100Insulin Degludec181$135,464
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog74$126,886
JanuviaSitagliptin Phosphate96$99,730
RybelsusSemaglutide53$79,463
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog90$65,577
VascepaIcosapent Ethyl103$56,961
Tresiba Flextouch U-200Insulin Degludec44$55,120
TradjentaLinagliptin54$48,959
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt24$34,513
JanumetSitagliptin Phos/Metformin Hcl32$32,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,485$546,239408 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr$183$384,718322 claims
Lilly USA, LLCMounjaro, Trulicity$584$352,461253 claims
AstraZenecaFarxiga$146$194,307184 claims
MerckJanuvia, Janumet, Janumet Xr, Steglatro$105$171,716171 claims
AbbVieSynthroid$521$25,507309 claims
AmgenProlia$153$21,21512 claims
Esperion Therapeutics, Inc.Nexletol$63$20,94139 claims
BayerKerendia$218$16,10924 claims
Johnson & JohnsonInvokana$143$15,80720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Bluefield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →